1 Min Read
July 12 (Reuters) - Dimerix Ltd
* Reports positive results from phase 2a trial of DMX-200 in chronic kidney disease
* DMX-200 phase 2a clinical trial meets primary safety endpoint Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.